Biotech Companies Record Another Positive Quarter
Source: Peter Winter, BioWorld  (10/7/13)
"In all there were 27 public offering transactions generating $1.26 billion in the third quarter, with companies continuing to take advantage of their higher stock valuations and welcoming capital markets to raise funds for their operations." More >

Not All Stem Cells Are Created Equal: Vernon Bernardino
Source: Peter Byrne of The Life Sciences Report  (10/3/13)
Biotech companies are fiercely competing to create the newest and best miracle drugs using stem cell technologies. How can an investor spot the potentially victorious outliers amid the chaos of rival scientific claims? The failure rate of new product development in the only recently understood cell space is terrifying, but in this interview with The Life Sciences Report, analyst Vernon Bernardino of MLV & Co. reveals his formula for evaluating the strongest contenders. Bernardino also names five companies with products that may succeed in this new and competitive space. More >

3 Small-Cap Biotechnology Stocks Making Big Moves
Source: Tom Meyer, Wall St. Cheat Sheet  (10/1/13)
"Investors have seen a tremendous rally in the biotechnology industry. Many stocks have been participating in the rally, but there have been a few that are especially standing out because of performance and/or new announcements." More >

John McCamant Scans Under the Radar for Promising Biotechs
Source: Peter Byrne of The Life Sciences Report  (9/26/13)
With more than 25 years of experience in the biotech market, John McCamant, editor of the Medical Technology Stock Letter, understands how the seasons of the investment cycle can influence a company's value. But he sticks to the fundamentals: After all, a great pipeline and competent management can propel a biotech upward through blustery weather as well as blue sky. Find out how four companies fit his philosophy in this interview with The Life Sciences Report. More >

Muscling into the Nutritional Supplements Market: Brad Pyatt
Source: George S. Mack of The Life Sciences Report  (9/26/13)
Sports analogies are used way too often in business, but MusclePharm Corp.'s Founder, President and CEO Brad Pyatt has used his experience as a wide receiver in the National Football League to build a nutritional supplement business, employing leadership tools he learned from great coaches and players. In this interview with The Life Sciences Report, Pyatt talks about his young company's explosive growth, and how he expects to continue expanding both revenue and earnings to generate tremendous shareholder value. More >

In Vitro Diagnostics Growth to Spearhead Future of Medtech
Source: Elizabeth Cairns, EP Vantage  (9/23/13)
"The analysis of the top 20 sectors of the worldwide medical device market reveals that the IVD sector is expanding at a CAGR of 5.1%, outpacing the overall medtech market growth rate of 4.5%." More >

Provectus Pharmaceuticals Inc. and PV-10: Rose Bengal as a Novel Cancer Therapeutic
Source: Daniel Levy of The Life Sciences Report  (9/19/13)
Despite all of the advances in diagnosis and treatment, the family of diseases that falls under the umbrella of "cancer" still represents a significant unmet medical need. Consequently, research continues in the discovery and development of therapeutic agents with novel mechanisms of action, wider therapeutic indexes and lower overall toxicities. In this interview with The Life Sciences Report, Peter Culpepper, CFO and COO of Provectus Pharmaceuticals Inc., describes his company's innovative rose bengal formulation and its use as a cancer therapeutic. More >

Four Small-Cap Growth Names with Different Value Drivers: Keay Nakae
Source: George S. Mack of The Life Sciences Report  (9/19/13)
It's important to take the emotion out of investing. Keay Nakae, senior research analyst with Ascendiant Capital Markets, looks at micro- and small-cap biotech stocks from an engineer's perspective: It's all about the data. In this interview with The Life Sciences Report, Nakae reports on four companies with upcoming catalysts that potentially position them for significant growth—and the ability to grab investors' attention. More >

The Next Step in Killing Cancer
Source: Martin Biancuzzo, The Daily Reckoning  (9/16/13)
"After several years of trial and error, Olson and his team at the privately owned Seattle biotech firm Blaze Bioscience, have created something called 'tumor paint.' And the solution has come from the most unlikely of places. . .Scorpion venom." More >

Hidden Finds in Regenerative and Medical Technology: Jeff Cohen
Source: Peter Byrne of The Life Sciences Report  (9/12/13)
Ladenburg Thalmann & Co. Inc.'s Jeff Cohen regularly explores the frontiers of regenerative and medical technology looking for solid investment opportunities. In this interview with The Life Sciences Report, Cohen reveals promising finds in one of the world's fastest-growing business sectors. From robotics to skin grafts, Cohen knows his science and his market. More >

Griffin Securities' Keith Markey Gives Performance Reviews on Four Favorite Biotech Names
Source: Peter Byrne of The Life Sciences Report  (9/12/13)
As science director for Griffin Securities, Keith Markey knows his way around the advanced technologies of the most promising research in biotech. In this interview with The Life Sciences Report, Markey explains the science behind new developments in the antibiotic, diabetic and dermatological fields, highlighting ground-floor investment opportunities that investors will not want to miss. More >

Medtech Stock Update: Public Policy Forces Restructuring, M&A Activity
Source: Zacks Equity Research  (9/10/13)
"The Patient Protection and Affordable Care Act (PPACA), particularly the medical device excise tax, has taken a heavy toll on the medtech sector, hurting pricing decisions of the companies and subjecting them to tremendous margin pressure." More >

Digging Below the Surface of Neurotechnology: Casey Lynch
Source: George S. Mack of The Life Sciences Report  (9/5/13)
Neuroscience is about as complex as it gets. The central nervous system contains the brain and spinal cord, where hundreds of billions of neurons are located—and that doesn't include the peripheral nervous system. Casey Lynch, managing director of NeuroInsights, works to make sense of both the disease processes affecting the nervous system and potential therapies that could help patients and enrich investors. In this interview with The Life Sciences Report, Lynch brings some clarity to the complexity, and speaks frankly about the wild goose that some Alzheimer's disease investigators have been chasing. More >

Medical Conference Schedule Sept. 2013 through March 2014
Source: Michael King, JP Morgan  (9/5/13)
More >

Scientific Conferences Create Buzz and Move Biotech Stocks: Michael King
Source: George S. Mack of The Life Sciences Report  (9/5/13)
It's that time again. From Labor Day through the New Year, analysts jet off to conferences across the U.S. and Europe to hear data they've been waiting on for years. Michael King, managing director and senior biotechnology analyst at JMP Securities, has been at this game for almost two decades, and he has a firm grip on how data releases about molecules and their targets will affect the biotech stocks in his coverage. In this interview with The Life Sciences Report, King also names four growth companies making important advances in hematologic cancers. Just in time. More >

Breakthrough Therapy Designation Speeds Up Drug Approvals
Source: Patricia Dimond, Genetic Engineering and Biotechnology News  (9/4/13)
"The FDA's new development path is specifically designed for experimental agents that produce large and unprecedented treatment effects in early clinical trials. If a drug is designated a breakthrough therapy, the FDA says it will expedite the development and review of the drug." More >

Biotech Investor Realism with Andrew Fein
Source: Peter Byrne of The Life Sciences Report  (8/29/13)
Expert healthcare company watcher Andrew Fein of H.C. Wainwright & Co. knows how the sausage is made in the stock analyst factory. And he doesn't pull any punches: In this interview with The Life Sciences Report, Fein dishes out praise for sticking to sellside fundamentals and suggests skimming off bloggers who have yet to earn their analytical chops. He rounds out the menu by naming biotech companies with the potential to rise to the top of the simmering biotech market. More >

Amgen Deal Highlights a Red-Hot Cancer Therapy Industry
Source: Tara Clarke, Money Morning  (8/26/13)
"Cancer therapy is a multibillion-dollar industry that will be the biggest M&A driver—and profit producer—for biotech investors." More >

Three New Picks from the Hot Biotech IPO Market: Ran Nussbaum
Source: George S. Mack of The Life Sciences Report  (8/22/13)
Ran Nussbaum, co-founder and managing partner of The Pontifax Group, is a venture capitalist seeking game-changing products that will create real value for patients, pharmas and investors. In this interview with The Life Sciences Report, Nussbaum addresses three public companies in different stages of development—from a penny stock with a preclinical value driver to a revenue-generating "larger" small-cap company developing novel products for critical orphan indications. As a bonus, Nussbaum drops two European biotech names that he believes are suffering from anonymity in U.S. markets. More >

Spot Tenbagger Discovery Potential in Biotech: Michael Berry
Source: George S. Mack of The Life Sciences Report  (8/22/13)
How do the best investors detect life science companies with the potential to generate significant wealth? Michael Berry, publisher of Morning Notes, found that traditional growth and value models didn't measure up, so he developed his own "discovery" strategy. He looks at companies that haven't gone public yet. He's not afraid of the penny stock. Find out more about Berry's technique, and about five companies that fit his profit-generating profile, in this interview with The Life Sciences Report. More >

Quest to Cure Cancer Spurs Big Gains in the Biotech Bull
Source: Ray Blanco, The Daily Reckoning  (8/20/13)
"There are still plenty of skeptics regarding the promise of this technology, but I'm not one of them. In fact, I believe biotechnology investors who don't participate in this new wave of cancer therapy will be missing out on historic profit opportunities." More >

Adventures in the Biotech Trade with Jim Letourneau
Source: Peter Byrne of The Life Sciences Report  (8/15/13)
Jim Letourneau, publisher of Big Picture Speculator, shares tales of strange biotechnologies worth buying into—such as cures for high dental bills and dog breath—in this interview with The Life Sciences Report. Letourneau likes to invest in biotech firms because their stock values are less volatile than commodity-based companies, which are chained to uncontrollable price fluctuations. You are advised to hold onto your brain (quite literally), while Letourneau describes a few curious—and potentially profitable—biotech investment adventures. More >

Still Time to Catch Big Growth in Biotech: George Zavoico
Source: George S. Mack of The Life Sciences Report  (8/15/13)
Biotech has had a scorching run for more than a year and a half, but as broader markets approach more realistic valuations with less potential upside, it becomes even more important to be invested in the right companies with truly meaningful catalysts on the horizon. George Zavoico of MLV & Co. knows how to pick winners from the field, and offers up solid ideas with visible growth drivers in this interview with The Life Sciences Report. Your inner gambler should take note: A beaten-down micro- or small-cap company might, with a bit of luck, bring home the gold. More >

The Best New Companies in a White-Hot Biotech Sector
Source: Michael Robinson, Money Morning  (8/9/13)
"IPO action is proof of the big bucks coming into biotech, igniting a strong rally in the entire sector for the rest of the year. So far this year, we've seen the most biotech IPOs in 13 years." More >

Wedbush Expert Declares Money for Biotech Is Still Out There
Source: George S. Mack of The Life Sciences Report  (8/8/13)
The bull market in biotech stocks is coming up on its two-year anniversary, and large-cap and many small-cap names have flourished in that time. But can it last? Greg Wade, managing director of Wedbush Securities, wants investors to know there's more to go, and that stocks are ready and willing to respond to good news from clinical trials and on the regulatory front. In this interview with The Life Sciences Report, Wade identifies six names that investors can take to the bank, one of which is still his favorite after two years. More >